279 related articles for article (PubMed ID: 22425710)
1. Case study: technology initiative led to advanced lead optimization screening processes at Bristol-Myers Squibb, 2004-2009.
Zhang L; Cvijic ME; Lippy J; Myslik J; Brenner SL; Binnie A; Houston JG
Drug Discov Today; 2012 Jul; 17(13-14):733-40. PubMed ID: 22425710
[TBL] [Abstract][Full Text] [Related]
2. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006.
Houston JG; Banks MN; Binnie A; Brenner S; O'Connell J; Petrillo EW
Drug Discov Today; 2008 Jan; 13(1-2):44-51. PubMed ID: 18190863
[TBL] [Abstract][Full Text] [Related]
3. Efficient and effective compound management to support lead optimization.
Johnson CW; Chatterjee M; Kubala S; Helm D; Houston J; Banks M
J Biomol Screen; 2009 Jun; 14(5):523-30. PubMed ID: 19483145
[TBL] [Abstract][Full Text] [Related]
4. Improving lead generation success through integrated methods: transcending 'drug discovery by numbers'.
Campbell JB
IDrugs; 2010 Dec; 13(12):874-9. PubMed ID: 21154146
[TBL] [Abstract][Full Text] [Related]
5. Alternative business models for drug discovery.
Bunin BA; Ekins S
Drug Discov Today; 2011 Aug; 16(15-16):643-5. PubMed ID: 21745585
[No Abstract] [Full Text] [Related]
6. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
7. How development and manufacturing will need to be structured--heads of development/manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
Nepveux K; Sherlock JP; Futran M; Thien M; Krumme M
J Pharm Sci; 2015 Mar; 104(3):850-64. PubMed ID: 25630721
[TBL] [Abstract][Full Text] [Related]
8. Novel trends in high-throughput screening.
Mayr LM; Bojanic D
Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
[TBL] [Abstract][Full Text] [Related]
9. Scientific workflows as productivity tools for drug discovery.
Shon J; Ohkawa H; Hammer J
Curr Opin Drug Discov Devel; 2008 May; 11(3):381-8. PubMed ID: 18428092
[TBL] [Abstract][Full Text] [Related]
10. Affinity-based screening techniques: their impact and benefit to increase the number of high quality leads.
Bergsdorf C; Ottl J
Expert Opin Drug Discov; 2010 Nov; 5(11):1095-107. PubMed ID: 22827747
[TBL] [Abstract][Full Text] [Related]
11. Biotechnology partnerships--medicine for an ailing industry?
DeLamarter J
Nat Biotechnol; 2003 Aug; 21(8):847-8. PubMed ID: 12894192
[No Abstract] [Full Text] [Related]
12. Natural products as catalysts for innovation: a pharmaceutical industry perspective.
Schmitt EK; Moore CM; Krastel P; Petersen F
Curr Opin Chem Biol; 2011 Aug; 15(4):497-504. PubMed ID: 21684800
[TBL] [Abstract][Full Text] [Related]
13. Advances in improving the quality and flexibility of compound management.
Janzen WP; Popa-Burke IG
J Biomol Screen; 2009 Jun; 14(5):444-51. PubMed ID: 19483148
[TBL] [Abstract][Full Text] [Related]
14. Quality by design in lead optimization: a new strategy to address productivity in drug discovery.
Rossi T; Braggio S
Curr Opin Pharmacol; 2011 Oct; 11(5):515-20. PubMed ID: 21652263
[TBL] [Abstract][Full Text] [Related]
15. Approaches for high-throughput pharmacokinetic screening of low-molecular-weight drug candidates.
Fontana S
Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):139-42. PubMed ID: 24329157
[TBL] [Abstract][Full Text] [Related]
16. Lead optimization via high-throughput molecular docking.
Joseph-McCarthy D; Baber JC; Feyfant E; Thompson DC; Humblet C
Curr Opin Drug Discov Devel; 2007 May; 10(3):264-74. PubMed ID: 17554852
[TBL] [Abstract][Full Text] [Related]
17. Early phase drug discovery: cheminformatics and computational techniques in identifying lead series.
Duffy BC; Zhu L; Decornez H; Kitchen DB
Bioorg Med Chem; 2012 Sep; 20(18):5324-42. PubMed ID: 22938785
[TBL] [Abstract][Full Text] [Related]
18. From virtuality to reality - Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective.
Rester U
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):559-68. PubMed ID: 18600572
[TBL] [Abstract][Full Text] [Related]
19. Best practices in compound management for preserving compound integrity and accurately providing samples for assays.
Matson SL; Chatterjee M; Stock DA; Leet JE; Dumas EA; Ferrante CD; Monahan WE; Cook LS; Watson J; Cloutier NJ; Ferrante MA; Houston JG; Banks MN
J Biomol Screen; 2009 Jun; 14(5):476-84. PubMed ID: 19483144
[TBL] [Abstract][Full Text] [Related]
20. The future of pharmaceutical manufacturing in the context of the scientific, social, technological and economic evolution.
Stegemann S
Eur J Pharm Sci; 2016 Jul; 90():8-13. PubMed ID: 26542345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
